logo

LICN

Lichen International·NASDAQ
--
--(--)
--
--(--)
8.52 / 10
Outperform

Fundamental measurement shows superior quality (8.5/10). Constructive metrics: Current ratio and Total assets turnover ratio, balanced by issues in Total profit / EBIT (%) and Current assets turnover ratio. Final assessment: very promising.

Fundamental(8.52)SentimentTechnical

Analysis Checks(3/10)

Asset-liability ratio (%)
Value4.40
Score0/3
Weight-0.78%
1M Return-1.46%
Total operating revenue (YoY growth rate %)
Value-21.20
Score0/3
Weight-0.95%
1M Return-1.96%
Equity multiplier
Value1.05
Score0/3
Weight-0.53%
1M Return-1.02%
ROE (diluted) (YoY growth rate %)
Value-14.71
Score3/3
Weight56.46%
1M Return82.15%
Equity ratio (Total liabilities / Shareholders’ equity attributable to parent company) (%)
Value0.05
Score0/3
Weight-0.39%
1M Return-0.75%
Total profit / EBIT (%)
Value99.88
Score0/3
Weight-1.19%
1M Return-2.50%
Current assets turnover ratio
Value0.46
Score0/3
Weight-0.84%
1M Return-1.65%
Operating revenue (YoY growth rate %)
Value-21.20
Score0/3
Weight-1.03%
1M Return-2.13%
Total assets turnover ratio
Value0.19
Score3/3
Weight48.81%
1M Return79.11%
Current ratio
Value10.19
Score2/3
Weight0.43%
1M Return0.77%
Is LICN undervalued or overvalued?
  • LICN scores 8.52/10 on fundamentals and holds a Discounted valuation at present. Backed by its -13.38% ROE, -42.69% net margin, -3.13 P/E ratio, 0.79 P/B ratio, and -222.73% earnings growth, these metrics solidify its Outperform investment rating.